Switch theme
Sign up to access all valuation multiples
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.
2002
7
LTM Revenue n/a
LTM EBITDA -$16.7M
$6.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Grace Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of -$16.7M.
In the most recent fiscal year, Grace Therapeutics achieved revenue of n/a and an EBITDA of -$11.3M.
Grace Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Grace Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$18.1M | -$11.3M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$9.8M | -$42.4M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Grace Therapeutics's stock price is $2.
Grace Therapeutics has current market cap of $29.4M, and EV of $6.4M.
See Grace Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6.4M | $29.4M | XXX | XXX | XXX | XXX | $-1.09 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Grace Therapeutics has market cap of $29.4M and EV of $6.4M.
Grace Therapeutics's trades at n/a LTM EV/Revenue multiple, and -0.4x LTM EBITDA.
Analysts estimate Grace Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Grace Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $6.4M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -0.4x | XXX | XXX | XXX |
| P/E | -2.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -0.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpGrace Therapeutics's NTM/LTM revenue growth is Infinity%
Grace Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.6M for the same period.
Over next 12 months, Grace Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Grace Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Grace Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -37% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.6M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Grace Therapeutics acquired XXX companies to date.
Last acquisition by Grace Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Grace Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Grace Therapeutics founded? | Grace Therapeutics was founded in 2002. |
| Where is Grace Therapeutics headquartered? | Grace Therapeutics is headquartered in United States of America. |
| How many employees does Grace Therapeutics have? | As of today, Grace Therapeutics has 7 employees. |
| Who is the CEO of Grace Therapeutics? | Grace Therapeutics's CEO is Mr. Prashant Kohli. |
| Is Grace Therapeutics publicy listed? | Yes, Grace Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Grace Therapeutics? | Grace Therapeutics trades under GRCE ticker. |
| When did Grace Therapeutics go public? | Grace Therapeutics went public in 2011. |
| Who are competitors of Grace Therapeutics? | Similar companies to Grace Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Grace Therapeutics? | Grace Therapeutics's current market cap is $29.4M |
| What is the current EBITDA of Grace Therapeutics? | Grace Therapeutics's last 12-month EBITDA is -$16.7M. |
| What is the current EV/EBITDA multiple of Grace Therapeutics? | Current EBITDA multiple of Grace Therapeutics is -0.4x. |
| Is Grace Therapeutics profitable? | Yes, Grace Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
